Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen.

被引:0
|
作者
Garber, JE
Halabi, S
Kaplan, E
Edge, S
Dressler, L
Paskett, E
Berliner, N
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Duke Univ, Durham, NC 27706 USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Yale Univ, Sch Med, New Haven, CT 06520 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
下载
收藏
页码:6S / 6S
页数:1
相关论文
共 50 条
  • [41] Prevalence of Factor V Leiden (FVL, G1691A) and F-II (G20210A) Mutations in Jordanian Atherosclerotic Patients
    Jaradat, Ahmad Q.
    BIOCHEMISTRY MOSCOW-SUPPLEMENT SERIES B-BIOMEDICAL CHEMISTRY, 2023, 17 (04) : 189 - 193
  • [42] 10 year event-free survival (EFS) in postmenopausal women with early stage breast cancer during the second five years after adjuvant tamoxifen.
    Kennecke, H
    Speers, C
    Chia, S
    Norris, B
    Gelmon, K
    Bryce, C
    Barnett, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S57 - S58
  • [43] Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
    Romero, Sally A. D.
    Young, Katie
    Hickey, Martha
    Su, H. Irene
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (12):
  • [44] Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen
    Zhu, Yunshan
    Yang, Jianhua
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2013, 39 (09) : 1411 - 1414
  • [45] Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer
    Zidan, J
    Rubenstein, W
    ONCOLOGY, 1999, 56 (01) : 43 - 45
  • [46] Survival with adjuvant surgical oophorectomy and tamoxifen in premenopausal women with operable breast cancer
    Love, R. R.
    Dinh, N. V.
    Quy, T. T.
    Linh, N. D.
    Hade, E. M.
    Young, G. S.
    Jarjoura, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Prevalence of Factor V Leiden (FVL, G1691A) and F-II (G20210A) Mutations in Jordanian Atherosclerotic Patients
    Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry, 2023, 17 : 189 - 193
  • [48] Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer
    Silliman, RA
    Guadagnoli, E
    Rakowski, W
    Landrum, MB
    Lash, TL
    Wolf, R
    Fink, A
    Ganz, PA
    Gurwitz, J
    Borbas, C
    Mor, V
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2680 - 2688
  • [49] Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
    Chin, Jason
    Konje, Justin C.
    Hickey, Martha
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (04):
  • [50] Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen
    KalefEzra, JA
    Pavlidis, N
    Klouvas, G
    Karantanas, A
    Hatzikonstantinou, I
    Glaros, D
    BREAST CANCER RESEARCH AND TREATMENT, 1996, 37 (02) : 161 - 168